ClinicalTrials.gg
Not yet recruitingNCT07490327Updated Mar 24, 2026

Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia

A Phase 1/2 interventional study of AD-303A and AD-3031 in Androgenetic Alopecia, sponsored by Moogene Medi Co., Ltd. Not yet recruiting at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Moogene Medi Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Alopecia with a site in Korea, Republic of — 5 open to participants now, 5 under way, 3 of them phase 3. Alopecia · Korea, Republic of.

Planned enrollment
18th of 21
30 · median 80
Started
2026
with 1 other
Phase 1/2
3 of 22
2 open now
Registered
20th of 22
by date

Among the 22 studies in Alopecia with a site in Korea, Republic of, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 20th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

5 of the 22 studies in Alopecia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Alopecia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • AD-303A / AD-3031
  • Androgenetic Alopecia
  • Dutasteride
  • Topical
  • 5-Alpha Reductase Inhibitor
  • Pharmacokinetics
  • Safety
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants aged 19 to 55 years.
  • Clinical diagnosis of androgenetic alopecia.
  • Healthy as determined by medical history, physical examination, vital signs, (ECG), and clinical laboratory tests.
  • Willing and able to comply with all study procedures and visit schedules.

Exclusion criteria

Exclusion Criteria:

  • History or presence of dermatologic conditions affecting the scalp other than androgenetic alopecia.
  • Prior hair transplantation or scalp surgery that may affect evaluation of hair growth.
  • Use of medications known to affect hair growth (e.g., finasteride, dutasteride, minoxidil) within 6 months prior to screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    AD-303A Topical

    Participants receive topical AD-303A applied to the scalp according to the study protocol.

    Drug: AD-303A

  • Active comparator
    Oral AD-3031

    Participants receive oral AD-3031 administered according to the study protocol.

    Drug: AD-3031

Interventions

  • DrugAD-303A

    Topical AD-303A applied to the scalp according to the study protocol.

  • DrugAD-3031

    Oral AD-3031 administered according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of dutasteride

    The maximum observed plasma concentration (Cmax) of dutasteride following administration of the study drug.

    Time frame: Up to Day14

Secondary outcomes

  1. Change from baseline in scalp dihydrotestosterone (DHT) concentration Description

    Change from baseline in scalp tissue dihydrotestosterone (DHT) concentration measured following repeated administration of topical dutasteride.

    Time frame: Baseline to Day 8

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Phase 1/2a

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Sep 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 24, 2026
StartEst.
Apr 2026
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07490327
Lead sponsor
Moogene Medi Co., Ltd
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Apr 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Ji-Hye Lee, Ph.D.
Contact
jhlee@moogene.com
82-31-8027-6150
Tae-Jong Yoon, Ph.D.
Contact
moogenemedi@moogene.com
82-31-8027-6150
Seung Hwan Lee, Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion